Jesus G. Berdeja

Director of Multiple Myeloma Research
Sarah Cannon Research Institute and Tennessee Oncology

Poster(s):

• (PA-076) Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
  Wednesday, September 17, 2025